Journal article · 2014 · Open access
Targeting Akt3 Signaling in Triple-Negative Breast Cancer
Cancer Research, 74(3), 964–973 · Published 1 February 2014 · DOI 10.1158/0008-5472.can-13-2175
In brief
“Targeting Akt3 Signaling in Triple-Negative Breast Cancer” is a 2014 journal article by Y. Rebecca Chin and 5 co-authors, published in Cancer Research. OpenAlex counts 167 citations as of 21 November 2026. It is open access: the full text is free to read at PubMed Central.
- Citations
- 167
- Most cited in
- 2021 (17)
- Field-weighted impact
- 4.77
- References
- 44
- Authors
- 6
Abstract
Triple-negative breast cancer (TNBC) is currently the only major breast tumor subtype without effective targeted therapy and, as a consequence, in general has a poor outcome. To identify new therapeutic targets in TNBC, we performed a short hairpin RNA (shRNA) screen for protein kinases commonly amplified and overexpressed in breast cancer. Using this approach, we identified AKT3 as a gene preferentially required for the growth of TNBCs. Downregulation of Akt3 significantly inhibits the growth of TNBC lines in three-dimensional (3D) spheroid cultures and in mouse xenograft models, whereas loss of Akt1 or Akt2 have more modest effects. Akt3 silencing markedly upregulates the p27 cell-cycle inhibitor and this is critical for the ability of Akt3 to inhibit spheroid growth. In contrast with Akt1, Akt3 silencing results in only a minor enhancement of migration and does not promote invasion. Depletion of Akt3 in TNBC sensitizes cells to the pan-Akt inhibitor GSK690693. These results imply that Akt3 has a specific function in TNBCs; thus, its therapeutic targeting may provide a new treatment option for this tumor subtype.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Chin, Y. R., Yoshida, T., Marusyk, A., Beck, A. H., Polyák, K., & Toker, A. (2014). Targeting Akt3 Signaling in Triple-Negative Breast Cancer. Cancer Research, 74(3), 964–973. https://doi.org/10.1158/0008-5472.can-13-2175
MLA 9
Chin, Y. Rebecca, et al. “Targeting Akt3 Signaling in Triple-Negative Breast Cancer.” Cancer Research, vol. 74, no. 3, 2014, pp. 964–973. https://doi.org/10.1158/0008-5472.can-13-2175.
Chicago
Chin, Y. Rebecca, Taku Yoshida, Andriy Marusyk, Andrew H. Beck, Kornélia Polyák, and Alex Toker. 2014. “Targeting Akt3 Signaling in Triple-Negative Breast Cancer.” Cancer Research 74 (3): 964–973. https://doi.org/10.1158/0008-5472.can-13-2175.
Harvard
Chin, Y. R. et al. (2014) ‘Targeting Akt3 Signaling in Triple-Negative Breast Cancer’, Cancer Research, 74(3), pp. 964–973. doi:10.1158/0008-5472.can-13-2175.
IEEE
Y. R. Chin, T. Yoshida, A. Marusyk, A. H. Beck, K. Polyák, and A. Toker, “Targeting Akt3 Signaling in Triple-Negative Breast Cancer,” Cancer Research, vol. 74, no. 3, pp. 964–973, 2014, doi: 10.1158/0008-5472.can-13-2175.
BibTeX
@article{chin2014targeting,
title = {{Targeting Akt3 Signaling in Triple-Negative Breast Cancer}},
author = {Chin, Y. Rebecca and Yoshida, Taku and Marusyk, Andriy and Beck, Andrew H. and Polyák, Kornélia and Toker, Alex},
journal = {Cancer Research},
year = {2014},
volume = {74},
number = {3},
pages = {964--973},
doi = {10.1158/0008-5472.can-13-2175},
url = {https://doi.org/10.1158/0008-5472.can-13-2175}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2017 | 16 | |
| 2018 | 14 | |
| 2019 | 16 | |
| 2020 | 10 | |
| 2021 | 17 | |
| 2022 | 13 | |
| 2023 | 9 | |
| 2024 | 16 | |
| 2025 | 12 | |
| 2026 | 8 |
Its field-weighted citation impact is 4.77: it has been cited 4.77 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- triple-negative breast cancer
- AKT3
- Akt signaling
- AKT1
- AKT2
- p27
- cell cycle inhibition
- tumor growth
Work with this paper
Most-cited papers in Biochemistry, Genetics and Molecular Biology
- PROTEIN MEASUREMENT WITH THE FOLIN PHENOL REAGENTOliver H. Lowry, NiraJ. Rosebrough, A. Lewis Farr and 1 more · Journal of Biological Chemistry · 1951 · 316,470 citations
- A Rapid and Sensitive Method for the Quantitation of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye BindingM Bradford · Analytical Biochemistry · 1976 · 256,780 citations
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodKenneth J. Livak, Thomas D. Schmittgen · Methods · 2001 · 184,418 citations
- Molecular Cloning: A Laboratory ManualJoseph Sambrook, Elisabeth Fritsch, Tom Maniatis · UCLA - Biblioteca de Ciencias de la Salud · 1989 · 133,493 citations
- Basic Local Alignment Search ToolStephen F. Altschul, Warren R. Gish, Webb Miller and 2 more · Journal of Molecular Biology · 1990 · 100,529 citations
All highly cited Biochemistry, Genetics and Molecular Biology papers
Questions about this paper
How do I cite this paper in APA style?
Chin, Y. R., Yoshida, T., Marusyk, A., Beck, A. H., Polyák, K., & Toker, A. (2014). Targeting Akt3 Signaling in Triple-Negative Breast Cancer. Cancer Research, 74(3), 964–973. https://doi.org/10.1158/0008-5472.can-13-2175
How many times has this paper been cited?
167 times, according to OpenAlex on 21 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at PubMed Central: sign in and open the full text from this page.
Who wrote this paper?
Y. Rebecca Chin, Taku Yoshida, Andriy Marusyk, Andrew H. Beck, Kornélia Polyák, Alex Toker.
What is the DOI of this paper?
10.1158/0008-5472.can-13-2175, permanently at https://doi.org/10.1158/0008-5472.can-13-2175. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 21 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.